Learn About Ewing Sarcoma

What is the definition of Ewing Sarcoma?

Ewing sarcoma is a cancerous tumor that occurs in bones or soft tissues, such as cartilage or nerves. There are several types of Ewing sarcoma, including Ewing sarcoma of bone, extraosseous Ewing sarcoma, peripheral primitive neuroectodermal tumor (pPNET), and Askin tumor. These tumors are considered to be related because they have similar genetic causes. These types of Ewing sarcoma can be distinguished from one another by the tissue in which the tumor develops. Approximately 87 percent of Ewing sarcomas are Ewing sarcoma of bone, which is a bone tumor that usually occurs in the thigh bones (femurs), pelvis, ribs, or shoulder blades. Extraosseous (or extraskeletal) Ewing sarcoma describes tumors in the soft tissues around bones, such as cartilage. pPNETs occur in nerve tissue and can be found in many parts of the body. A type of pPNET found in the chest is called Askin tumor.

What are the causes of Ewing Sarcoma?

The most common mutation that causes Ewing sarcoma involves two genes, the EWSR1 gene on chromosome 22 and the FLI1 gene on chromosome 11. A rearrangement (translocation) of genetic material between chromosomes 22 and 11, written as t(11;22), fuses part of the EWSR1 gene with part of the FLI1 gene, creating the EWSR1/FLI1 fusion gene. This mutation is acquired during a person's lifetime and is present only in tumor cells. This type of genetic change, called a somatic mutation, is not inherited.

How prevalent is Ewing Sarcoma?

Approximately 3 per 1 million children each year are diagnosed with a Ewing sarcoma. It is estimated that, in the United States, 250 children are diagnosed with one of these types of tumor each year. Ewing sarcoma accounts for about 1.5 percent of all childhood cancers, and it is the second most common type of bone tumor in children (the most common type of bone cancer is called osteosarcoma).

Is Ewing Sarcoma an inherited disorder?

This condition is generally not inherited but arises from a mutation in the body's cells that occurs after conception. This alteration is called a somatic mutation.

Who are the top Ewing Sarcoma Local Doctors?
Peter Anderson
Elite in Ewing Sarcoma
Elite in Ewing Sarcoma

Cleveland Clinic Children's Outpatient Center

8950 Euclid Avenue, 
Cleveland, OH 
Experience:
50+ years
Languages Spoken:
English

Peter Anderson is a Pediatrics provider in Cleveland, Ohio. Dr. Anderson has been practicing medicine for over 50 years and is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Osteosarcoma, Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, and Adult Soft Tissue Sarcoma.

Mitchell Cairo
Elite in Ewing Sarcoma
Hematology | Oncology
Elite in Ewing Sarcoma
Hematology | Oncology

Bradhurst Avenue Specialty Office

19 Bradhurst Avenue, 
Hawthorne, NY 
Languages Spoken:
English

Mitchell Cairo is a Hematologist and an Oncologist in Hawthorne, New York. Dr. Cairo is rated as an Elite provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Burkitt Lymphoma, B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma (PMBCL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Nicholas P. Webber
Distinguished in Ewing Sarcoma
Distinguished in Ewing Sarcoma

Aurora Orthopedics

2801 W Kinnickinnic River Pkwy, Ste 370, 
Milwaukee, WI 
Languages Spoken:
English

Nicholas Webber is an Orthopedics provider in Milwaukee, Wisconsin. Dr. Webber is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Osteoarthritis, Osteonecrosis, Adult Soft Tissue Sarcoma, Hip Replacement, and Knee Replacement.

What are the latest Ewing Sarcoma Clinical Trials?
Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas

Summary: Phase II trial with three independent strata to independently assess the effects of the association of pembrolizumab and cabozantinib in advanced sarcomas.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

Summary: This single arm study is designed to demonstrate the feasibility of a radically different approach for an exceptionally high-risk subset of MES with widely metastatic disease (WMES). We incorporate the use of evolutionary principles that apply to species and population dynamics as related to adaptation and extinction to populations of cancer cells that similarly adapt and that we are attempting to...

Who are the sources who wrote this article ?

Published Date: June 01, 2016
Published By: National Institutes of Health